A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity

Intravitreal Conbercept (IVC) is the latest applied and effective treatment for the management of retinopathy of prematurity (ROP). However, conbercept escapes from the vitreous into the general circulation and reduce systemic VEGF concentrations. Thus, there are concerns about systemic complication...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yong, Meng, Qingyu, Linghu, Dandan, Zhao, Mingwei, Liang, Jianhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048142/
https://www.ncbi.nlm.nih.gov/pubmed/30013230
http://dx.doi.org/10.1038/s41598-018-28987-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048142/
https://www.ncbi.nlm.nih.gov/pubmed/30013230
http://dx.doi.org/10.1038/s41598-018-28987-6

Ejemplares similares